Related Experiment Video
Updated: Aug 14, 2025
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.3K
Pomalidomide-induced lung injury: A case report.
Alexandre Vivien1, Julien Ancel1,2, Sophie Godet3
1Department of Respiratory Diseases, Reims University Hospital, Reims, France.
Medicine
|January 13, 2023
Summary
Pomalidomide can cause rare but serious lung injury in multiple myeloma patients. Discontinuing the drug led to rapid symptom and CT scan recovery, highlighting the importance of identifying drug toxicity.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Pomalidomide is an immunomodulatory imide drug utilized in treating multiple myeloma and Kaposi sarcoma.
- Its use is increasing, necessitating awareness of potential adverse events.
Observation:
- A 72-year-old male on dexamethasone, pomalidomide, and daratumumab for multiple myeloma developed dyspnea and hypoxemia.
- Symptoms included inflammatory syndrome, CT scan ground-glass opacities, and lymphocytic/eosinophilic alveolitis, appearing two months after starting pomalidomide.
Findings:
- Initial antibiotic treatment post-bronchoscopy showed no improvement.
- Discontinuation of pomalidomide, while continuing daratumumab and dexamethasone, resulted in rapid resolution of respiratory symptoms and CT scan abnormalities.
- No recurrence of dyspnea was noted during a 15-month follow-up period.
Implications:
- Pomalidomide-induced lung injury is a rare, serious adverse event that can manifest early in treatment.
- Prompt identification and discontinuation of pomalidomide are crucial for managing this toxicity.
- Increased vigilance for drug-induced lung injury is essential given the expanding use of pomalidomide in hematologic malignancies.
Related Concept Videos
01:26Pneumothorax-I
282
A pneumothorax is a condition where air builds up in the space between the lung and the chest wall, causing the lung to collapse. This condition arises when air enters the space between the parietal and visceral pleura, disrupting the negative pressure essential for lung inflation. This can lead to a partial or complete collapse of the lung.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
282
01:29Pulmonary Embolism I: Introduction
19
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
19
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
24
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
24
01:27Pneumothorax-II
258
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
258
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.9K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.9K
01:28Pleural Effusion II: Symptoms and Management
241
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
241